A buffered aspirin tablet composed of a uniform mixture of aqueous-based polymer coated aspirin, a buffering system and a hydrophillic gel-forming matrix material. The buffering system and matrix material provide a microenvironment on in vitro dissolution of about pH 5. The tablet does not require the use of multilayers and may be prepared by direct compression with conventional equipment.

Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.

Aspirin triggered lipid mediators (ATLMs) are disclosed which are useful for the treatment of prevention of inflammation associated with various diseases, including ischemia.

A pill box comprising a tray and a cover hingedly attached thereto. The lid and tray having nesting walls of which the front walls are formed with complementary frictional latch means. A pair of detents is provided along the tray side walls so as to provide a fulcrum about which the lid is rocked. Pressure forces are required to be applied simultaneously at the rear corners of the lid to open the box.

Timed-release aspirin is made by coating particles of aspirin prior to tabletting with a coating solution containing cellulose acetate phthalate. The tablet so produced remains substantially in tact while in the stomach and dissolves at a slow, controlled rate in the intestinal tract. Aspirin tablets providing both immediate pain relief and timed-release are produced by pressing separate layers of aspirin particles coated in this manner and ordinary uncoated aspirin into a double-layered tablet.

Compositions in which aspirin is present in combination with alkaline compounds, especially those containing water of crystallization (hydrates), deteriorate on standing. This deterioration may take several forms: It can be a physical deterioration in which such aspirin compositions become completely unmanageable, wet, gummy, sticky masses; or chemical decomposition in which aspirin loses its molecular structure chiefly by losing the acetyl group. The latter is accompanied by formation of acetic...

Coated aspirin tablets/caplets are provided wherein acetylsalicylic acid decomposition is inhibited by incorporation therein prior to coating of citric, alginic or glutamic acids of mixtures thereof.

For better control of pain, fever, inflammation and platelet aggregation in the human blood system, a tablet containing a relatively smaller amount of aspirin capable of rapid dissolution or disintegration in the oral, preferably sublingual, cavity permitting rapid absorption of the aspirin from the saliva into the blood system, and method of using such tablet.

The present invention provides a method for the synthesis of acetyl salicylic acid comprising mixing acetic anhydride and salicylic acid in approximately or exactly stoichiometric proportions and calcium oxide or zinc oxide, obtaining a yield of a mixture of acetyl salicylic acid and calcium acetate or zinc acetate with 2% maximum of free salicylic acid content. The reaction is fast, exothermic, one-pot, non-pollutant of the environment due to the fact that it doesn't require elimination of acid...

Enteric coated aspirin tablets rendered shock-insensitive by the provision of a protective coat of hydroxyproply methylcellulose of at least about 1.5% by weight based on the weight of the tablet core.